Skip to main content
An official website of the United States government

Mirvetuximab Soravtansine-gynx

Placeholder slot
 (MEER-veh-TUK-sih-mab SOH-rav-TAN-seen)

This page contains brief information about mirvetuximab soravtansine-gynx and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

US Brand Name(s)
Elahere
FDA Approved
Yes

FDA label information for this drug is available at DailyMed.

Use in Cancer

Mirvetuximab soravtansine-gynx is approved to treat:

Mirvetuximab soravtansine-gynx is approved under FDA’s Accelerated Approval Program. As a condition of approval, confirmatory trial(s) must show that it provides a clinical benefit in these patients.

Mirvetuximab soravtansine-gynx is also being studied in the treatment of other types of cancer.

More About Mirvetuximab Soravtansine-gynx

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

Research Results and Related Resources

Targeted Cancer Therapies

Monoclonal Antibodies

Clinical Trials Accepting Patients

Find Clinical Trials for Mirvetuximab Soravtansine - Check for trials from NCI's list of cancer clinical trials now accepting patients.

  • Posted:
  • Updated:
Email